Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NER1008 is a rectal enema formulation containing polyethylene glycol 3350 (PEG3350), developed by Norgine for bowel cleansing prior to flexible sigmoidoscopy. It functions as an osmotic laxative, where the PEG3350 polymer retains water within the rectum and sigmoid colon. This increases the volume of the stool, leading to rectal distension and triggering the natural urge to evacuate, thereby clearing the distal colon of solid matter. This preparation is intended to provide a clear view for endoscopic procedures without the need for extensive dietary restrictions or oral bowel preparations. While it contains a pharmaceutical active ingredient, it is classified as a medical device in some clinical contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NER1008.